

AMCoR

Asahikawa Medical College Repository <http://amcor.asahikawa-med.ac.jp/>

Molecular Human Reproduction (2004) 10(10):729–733.

Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss

Saijo, Y. ; Sata, F. ; Yamada, H. ; Suzuki, K. ; Sasaki, S. ;
Kondo, T. ; Gong, Y. ; Kato, EH. ; Shimada, S. ; Morikawa,
M. ; Minakami, H. ; Kishi, R.

1 *Running title: Ah receptor, P450 gene and the risk of recurrent pregnancy loss*

2

3

4 **Ah receptor, CYP1A1, CYP1A2 and CYP1B1 Gene Polymorphisms**
5 **are not involved in the Risk of Recurrent Pregnancy Loss**

6

7

8 **Y. Saijo^{1,3}, F. Sata¹, H. Yamada², K. Suzuki¹, S. Sasaki¹, T. Kondo¹, Y. Gong¹, E.H.**

9 **Kato², S. Shimada², M. Morikawa², H. Minakami² and R.Kishi¹**

10

11 ¹Department of Public Health, and ²Department of Obstetrics and Gynecology,

12 Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo

13 060-8638, Japan

14

15 ³To whom correspondence should be addressed. E-mail: y-saijo@med.hokudai.ac.jp

16 Telephone, +81 11 706 5068

17 Fax, +81 11 706 7805

18

1 The etiology of recurrent pregnancy loss (RPL) remains unclear, but it may be related
2 to a possible genetic predisposition together with involvement of environmental factors.
3 We examined the relation between RPL and polymorphisms in four genes, human aryl
4 hydrocarbon (Ah) receptor, CYP1A1, CYP1A2 and CYP1B1, which are involved in
5 the metabolism of a wide range of environmental toxins and carcinogens. All cases and
6 controls were women resident in Sapporo and the surrounding area. The *Ah receptor*,
7 *CYP1A1*, *CYP1A2* and *CYP1B1* genotypes were assessed in 113 Japanese women with
8 recurrent pregnancy loss (RPL) and 203 ethnically matched women experiencing at
9 least one live birth and no spontaneous abortion.

10 No significant differences in *Ah receptor*, *CYP1A1*, *CYP1A2* and *CYP1B1* genotype
11 frequencies were found between the RPL and the control (*Ah receptor*: Arg/Arg
12 (reference); Arg/Lys and Lys/Lys, odds ratio (OR) = 0.67; 95% confidence interval
13 (CI) = 0.40-1.11, *CYP1A1*: m1m1 (reference); m1m2 and m2m2, OR= 0.86; 95% CI=
14 0.53-1.40, *CYP1A2* : C/C and C/A (reference); A/A, OR= 1.16; 95% CI= 0.71-1.88,
15 *CYP1B1*: Leu/Leu (reference); Leu/Val and Val/Val, OR= 1.18; 95% CI= 0.68-2.02).

16 CONCLUSION: The present study suggests that the *Ah receptor*, *CYP1A1*, *CYP1A2*
17 and *CYP1B1* gene polymorphism are not major genetic regulators in RPL.

18 *Key words*: Ah receptor/CYP1A1/CYP1A2/CYP1B1/recurrent pregnancy loss

1 **Introduction**

2 About 10-14% of clinically recognized pregnancies end in pregnancy loss in the
3 Japanese population as in Caucasians. The etiology of recurrent pregnancy loss (RPL)
4 remains largely unclear (Stirrat, 1990; Parazzini *et al.*, 1991; Cramer and Wise, 2000;
5 Yamada, 2001). Epidemiological studies have suggested that the condition might be
6 multifactorial with a possible genetic predisposition and involvement of environmental
7 factors in its pathogenesis (Parazzini *et al.*, 1991; Cramer and Wise, 2000; Fenster *et*
8 *al.*, 1991).

9 Enzymes belonging to cytochrome P450 (CYP) families are involved in the
10 two-stage detoxification process of a wide range of environmental toxins and
11 carcinogens. The genes for these enzymes are part of the Ah gene battery and are under
12 Ah receptor control (Nebert and Gonzalez, 1987). The Ah receptor binds a number of
13 different classes of chemicals, including halogenated aromatics such as dioxin and
14 polycyclic aromatic hydrocarbons, which induce transcription of the genes in this
15 battery (Safe, 1995).

16 RPL is believed to be associated with various environmental toxins and
17 teratogens such as organic solvents, alcohol, heavy metals and ionizing radiation, but
18 scientifically accurate information regarding the reproductive impact of potential

1 environmental toxins and other teratogens is not readily available (Gardella and Hill,
2 2000). Maternal exposure to dioxin has been associated with increases in fetal loss and
3 reduction in birth weight in experimental studies in rodents and monkeys (Allen *et al.*,
4 1979; Bjerke *et al.*, 1994.; Courtney, 1976.; McNulty, 1984; Murray *et al.*, 1979.; Nau
5 *et al.*, 1986.; Umbreit *et al.*, 1987). Most of halogenated aromatic hydrocarbons such
6 as 2,3,7,8-tetrachlorodibenzo-*p* -dioxin (TCDD) are initiated by their binding to Ah
7 receptor. Following ligand binding the Ah receptor dimerizes with Ah receptor nuclear
8 translocator, and thereby acquires the ability to interact with dioxin response elements
9 that enhance transcription of genes encoding the CYP1A1, CYP1A2, and CYP1B1.
10 Each of these enzymes is inducible in human cells by halogenated aromatic
11 hydrocarbons via Ah receptor pathway (Li *et al.*, 1998) and each can convert activated
12 types of them (Larsen *et al.*, 1998; Turesky *et al.*, 1998; Williams and Phillips, 2000).

13 Recent studies have demonstrated that CYP family gene polymorphisms
14 significantly influence reproductive conditions. Wang and Zuckerman *et al.* (2002)
15 reported that *CYP1A1* gene polymorphism was associated with a reduction in birth
16 weight among women who smoked cigarettes in the United States. We previously
17 demonstrated that *CYP17* gene polymorphism was associated with risks of RPL (Sata
18 *et al.*, 2003b) and intrauterine fetal growth restriction in the Japanese population

1 (Yamada *et al.*, 2004).

2 The aim of this study was to investigate whether the *Ah receptor*, *CYP1A1*,
3 *CYP1A2*, and *CYP1B1* gene polymorphisms which are associated with impaired
4 detoxification were related to the pathogenesis of RPL.

1 **Materials and Methods**

2 This case-control study was performed in the city of Sapporo, Japan, during the years
3 1999-2003. We studied 113 patients aged 20-43 years with a history of RPL and 203
4 controls aged 21-49 years who were obstetrically managed in the Hokkaido University
5 Hospital. The characteristics of the study groups are shown in Table I. RPL was
6 defined as having a history of two or more spontaneous consecutive abortions and
7 stillbirths of less than 25 weeks of gestation. The primary RPL group comprised 99
8 women with a history of two or more spontaneous abortions but no live birth. The 14
9 secondary RPL women experienced three or more spontaneous abortions after at least
10 one live birth. A total of 105 miscarriages occurred in the first trimester. All women
11 with RPL were subjected to examination by ultrasound and hysterosalpingography for
12 detection of anatomical abnormalities of the genital tract and to chromosome
13 karyotypic analyses of peripheral blood. Couples who had balanced type chromosomal
14 translocation and women with a uterine conformational abnormality such as septate
15 uterus were excluded from this study. The control women consisted of 203 volunteers
16 experiencing at least one live birth, no spontaneous abortion and no history of
17 endometriosis or infertility. There were no significant differences in age between cases
18 and controls. This study was conducted with all the subjects' informed consent and

1 approved by the institutional ethical board for human gene and genome studies of
2 Hokkaido University Graduate School of Medicine.

3 Peripheral blood samples were thawed at room temperature, and after
4 thorough vortexing, 200µl was used to extract genomic DNA. QIAamp DNA Blood
5 Mini Kit (QIAGEN GmbH, Hilden, Germany) was used to purify DNA in accordance
6 with the manufacturer's instructions. The detailed method for the detection of the
7 *CYP1A1 MspI* polymorphism can be found elsewhere (Wu *et al.*, 1999). This method is
8 able to detect all 3 possible genotypes for the polymorphism: m1m1 (homozygous wild
9 type), m1m2 (heterozygous variant type), and m2m2 (homozygous variant type).

10 To analyze the *CYP1A2/ D* polymorphism, PCR amplifications were carried
11 out as described by Christiansen *et al.* (2000), using the primers 5-GGA AGG TAT
12 CAG CAG AAA GCC-3' and 5-GGC TCA TCC TTG ACA GTG CC-3. After the PCR
13 product was digested with *ApaI* endonuclease, the restriction digest was separated in a
14 3% agarose gel, generating a 255-bp fragment and a 371-bp fragment. The 626-bp
15 fragment represented the "A" allele (variant type). The 255-bp and 371-bp fragments
16 represented the "C" allele (wild type).

17 *Ah receptor* and *CYP1B1* gene polymorphisms were determined by the
18 TaqMan polymerase chain reaction (PCR) method using an MGB (Minor Groove

1 Binder) probe (de Kok *et al.*, 2002). To detect a polymorphism of Ah receptor at codon
2 554 G/A (Arg/Lys), two MGB probes were prepared; an G allele specific probe,
3 5'-FAM CAT GTG TCT GAT GTC T-MGB-3', and A allele specific probe, 5'-CTG
4 CAT GTG TTT GAT-MGB-3'. Each of the reporters was quenched by MGB, which
5 was typically located at the 3' end. The design of primers for PCR of the flanking
6 region of the G/A polymorphism in Ah receptor was as follow: forward, 5'-CAG CAT
7 AAT GAA AAA CCT AGG CAT T-3'; reverse, 5'- CAT CCG TTA AGT CAA TGT
8 CTC TCA A-3'. PCR was carried out using thermal cycler GeneAmp® PCR System
9 9700 (Applied Biosystems, Foster City, USA). During PCR cycles (initial denaturation
10 at 95°C for 10 min after 50°C for 2 min, followed by 40 cycles of 92°C for 30 s and 60
11 °C for 60 s), the fluorescence level of PCR products was measured using an ABI
12 PRISM 7000 Sequence Detector (Applied Biosystems), resulting in the clear
13 identification of three genotypes of *Ah receptor*. To detect a polymorphism of CYP1B1
14 at codon 432 C/G (Leu/Val), two MGB probes were prepared; a G allele specific probe,
15 5'-FAM ACC CAG TGA AGT GG-MGB-3', and C allele specific probe, 5'-ATG ACC
16 CAC TGA AGT G-MGB-3'. The design of primers for PCR of the flanking region of
17 the C/G polymorphism in *CYP1B1* was as follow: forward, 5'-TGT CAA CCA GTG
18 GTC TGT GAA TC-3'; reverse, 5'- TCA CTC TGC TGG TCA GGT CCT T-3'. PCR

1 was carried out employing the same PCR conditions as for Ah receptor analysis.

2 We calculated age-adjusted odds ratios (OR) and 95% confidence intervals
3 (CI) associated with the *Ah receptor*, *CYP1A1*, *CYP1A2*, and *CYP1B1* genotypes by
4 unconditional logistic regression analysis. Hardy-Weinberg equilibrium analyses were
5 performed to compare observed and expected genotype frequencies using a chi-square
6 test. All analyses were conducted using SPSS software for Windows version 12.0
7 (SPSS Inc., Chicago, U.S.A.).

1 **Results**

2 The characteristics of the study groups are shown in Table I. The frequencies
3 of the *Ah receptor*, *CYP1A1*, *CYP1A2* and *CYP1B1* genotypes in 113 cases with RPL
4 were compared with those in 203 controls in the Japanese population (Table II). The
5 distribution of all genotypes in each group was in Hardy-Weinberg equilibrium. There
6 was no significant difference in *Ah receptor*, *CYP1A1*, *CYP1A2* and *CYP1B1* genotype
7 frequencies between the women with RPL and the controls. The genotype frequencies
8 of *Ah receptor*, *CYP1A1*, *CYP1A2*, and *CYP1B1* in our control population resembled
9 those published earlier in Japan (Chida *et al.*, 1999; Kiyohara *et al.*, 2003; Sasaki *et al.*,
10 2003; Watanabe *et al.*, 2001).

11 We next evaluated the *Ah receptor*, *CYP1A1*, *CYP1A2* and *CYP1B1* genotypes
12 in both subgroups of women with three or more pregnancy losses (PLs) (Table III).
13 There was no significant difference in *Ah receptor*, *CYP1A1*, *CYP1A2* or *CYP1B1*
14 genotype frequencies between the women with RPL with three or more PLs and the
15 controls.

16

1 **Discussion**

2 The codon 554 G/A polymorphism in the *Ah receptor* gene appears to be a
3 determinant of the level of CYP1A1 inducibility in the Caucasian population (Smart
4 and Daly, 2000). However, no association was found between this polymorphism and
5 levels of CYP1A1 activity or lung cancer susceptibility in the Japanese population
6 (Kawajiri *et al.*, 1995). CYP1A1 is involved the metabolic activation of
7 benzo[a]pyrene, a widely distributed environmental carcinogen, which is found in
8 tobacco smoke. Maternal *CYP1A1 MspI* polymorphism was found to be associated
9 with a reduction in birth weight among women who smoked cigarettes, suggesting an
10 interaction between metabolic genes and environmental factors (Wang and Zuckerman
11 *et al.*, 2002). The authors demonstrated that mothers who smoked cigarettes and
12 carried the m2 allele of *CYP1A1* had a greater risk of delivering low birth weight
13 infants, while among mothers who had never smoked neither genotype had an
14 influence on birth weights of their infants. It is suggested that *CYP1A1 MspI* variant
15 genotypes increase enzyme activity (Landi *et al.*, 1994).

16 CYP1A2 is involved in the metabolic activation of numerous chemical
17 carcinogens-heterocyclic and aromatic amines and nitroaromatic compounds (Eaton *et*
18 *al.*, 1995), and in the biotransformation of many xenobiotics. *CYP1A2* genotype A/A

1 had a higher CYP1A2 inducibility than genotype G/A and G/G (Sachse *et al.*, 1999). It
2 was reported that a high CYP1A2 activity was associated with the risk of spontaneous
3 abortion, and that caffeine intakes positively related to the increased risk of
4 spontaneous abortion among women with high CYP1A2 activities (Signorello *et al.*,
5 2001). Serum levels of one of caffeine metabolites, paraxanthine, was found to relate
6 to an increased risk of spontaneous abortion (Klebanoff *et al.*, 1999). CYP1B1 also is
7 involved in the metabolic activation of benzo[a]pyrene (Luch *et al.*, 1998) and converts
8 estrogens to 4-hydroxy estrogens that induced DNA damage (Tang *et al.*, 1996). The
9 4-hydroxylation activities of 432G (variant) enzyme was 3-fold higher than the 432C
10 (wild) enzyme. Associations between the 432G and breast cancer (Hanna *et al.*, 2000),
11 and endometrial cancer (Sasaki *et al.*, 2003) were reported.

12 Recently, many investigations demonstrated that the maternal gene
13 polymorphisms related to RPL risks without consideration of burdens of environmental
14 factors (Yamada, *et al.*, 2004); these genes included factor V Leiden and prothrombin
15 mutations (Rey *et al.*, 2003), plasminogen activation inhibitor I and factor XIII
16 (Dossenbach-Glaninger *et al.*, 2003), HLA-G (Pfeiffer *et al.*, 2001; Aldrich *et al.*,
17 2001), GSTM1 (Sata *et al.*, 2003a), IL-1 (Unfried *et al.*, 2001; Wang and Yunis *et al.*,
18 2002; Karhukorpi *et al.*, 2003), IL-6 (Saijo *et al.*, 2004), CYP17 (Sata *et al.*, 2003b),

1 and NOS3 (Tempfer *et al.*, 2001). It is likely that RPL is a multifactorial polygenetic
2 disease. In the current study, however, no significant relationships between RPL and
3 *Ah receptor*, *CYP1A1*, *CYP1A2*, or *CYP1B1* polymorphisms were found; these gene
4 polymorphisms involved in altered detoxification ability were not major genetic
5 regulators in RPL when RPL risks was assessed without consideration of burdens
6 environmental factors.

7 Experimental animal studies have demonstrated that maternal exposure to
8 dioxin is associated with fetal loss and reduction in birth weight. However, there are
9 few epidemiological studies of the association between the maternal dioxin exposure
10 and pregnancy outcome in humans; and a study of the population exposed to a high
11 level of dioxin in Seveso showed no significant association between TCDD exposure
12 and adverse pregnancy outcome (Eskenazi *et al.*, 2003). Another recent study found no
13 association between blood dioxin levels and the *CYP1A1 Msp I* polymorphism,
14 although the sample size of this study was relatively small (n=28) (Tsuchiya *et al.*,
15 2003). Metabolic pathways of xenobiotics include their activation during phase I of the
16 biotransformation process followed by conjugation of highly toxic intermediate
17 metabolic products during phase II (Baranova *et al.*, 1999). The presence of deletions
18 of phase II enzymes such as GSTM1 rather than polymorphic phase I enzymes

1 including AhR batteries can provoke imbalanced interactions of phase I and II deeply
2 (Sata *et al.*, 2003a). Unfortunately, we did not evaluate the dioxin exposure levels in
3 the current study. Therefore, further studies are needed to clarify whether the
4 association between maternal dioxin exposure and pregnancy outcome can be modified
5 by xenobiotic gene polymorphisms.

6 Numbers of our study cases had 80% power to detect a true OR of 2.5, 2.1,
7 2.0, 2.1 for *Ah receptor*, *CYP1A1*, *CYP1A2*, *CYP1B1*, respectively, at the 0.05
8 significance level according to the genotype frequencies of our control group (Browner
9 et al., 2001). In order to elucidate the role of AhR gene battery and their gene
10 polymorphisms and to prove gene-environmental relationships in the RPL
11 pathophysiology, further studies are needed taking into account environmental factors
12 such as cigarette smoking, caffeine intake, and dioxin exposure.

13

14 **Acknowledgements**

15 This work was supported in part by Grants-in-aid for Scientific Research from the
16 Japan Society for the Promotion of Science and the Japan Ministry of Health, Labour
17 and Welfare. We thank for Ms. Sakuramachi, Mr. Haraguchi, Ms. Abe, Ms. Tanabe,
18 and Ms. Kunita for their technical assistance.

1 **References**

- 2 Aldrich, C.L., Stephenson, M.D., Karrison, T., Odem, R.R., Branch, D.W., Scott, J.R.,
3 Schreiber, J.R. and Ober, C. (2001) HLA-G genotypes and pregnancy outcome in
4 couples with unexplained recurrent miscarriage. *Mol Hum Reprod.*, **7**, 1167-72.
- 5 Allen, J., Barsotti, D., Lambrecht, L. and Van Miller, J. (1979) Reproductive effects
6 of halogenated aromatic hydrocarbons on nonhuman primates. *Ann NY Acad Sci.*,
7 **320**, 419-425.
- 8 Baranova, H., Canis, M., Ivaschenko, T., Albuissou, E., Bothorishvilli, R., Baranov, V.,
9 Malet, P. and Bruhat, M.A. (1999) Possible involvement of arylamine
10 N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the
11 development of endometriosis. *Mol. Hum. Reprod.*, **5**, 636-641.
- 12 Bjerke, D., Sommer, R., Moore, R. and Peterson, R. (1994) Effects of in utero and
13 lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposures on responsiveness of the
14 male rat reproductive system to testosterone stimulation in adulthood. *Toxicol Appl*
15 *Pharmacol.*, **127**, 250-257.
- 16 Browner, W.S., Newman T.B., Cummings, S.R. and Hulley, S.B. (2001) Estimating
17 sample size and power: the nitty-gritty. In Hulley, S.B., Cummings, S.R., Browner,
18 W.S., Grady, D., Hearst, N. and Newman T.B. (eds) *Designing Clinical Research*.

- 1 Lippincott Williams & Wilkins, Philadelphia, U.S.A., 65-91.
- 2 Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J. and Kamataki, T. (1999)
- 3 Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of
- 4 human CYP1A2 in the Japanese population. *Jpn J Cancer Res.*, **90**: 899-902.
- 5 Christiansen, L., Bygum, A., Jensen, A., Thomsen, K., Brandrup, F., Horder, M. and
- 6 Petersen, N.E. (2000) Association between CYP1A2 polymorphism and
- 7 susceptibility to porphyria cutanea tarda. *Hum Genet.*, **107**, 612-4.
- 8 Courtney, K.D. (1976) Mouse teratology studies with chlorodibenzo-p-dioxins. *Bull*
- 9 *Environ Contam Toxicol.*, **16**, 674-681.
- 10 Cramer, D.W. and Wise, L.A. (2000) The epidemiology of recurrent pregnancy loss.
- 11 *Semin. Reprod. Med.*, **18**, 331-339.
- 12 de Kok, J.B., Wiegerinck, E.T., Giesendorf, B.A. and Swinkels, D.W. (2002) Rapid
- 13 genotyping of single nucleotide polymorphisms using novel minor groove binding
- 14 DNA oligonucleotides (MGB probes). *Hum Mutat.*, **19**, 554-9.
- 15 Dossenbach-Glaninger, A., van Trotsenburg, M., Dossenbach, M., Oberkanins, C.,
- 16 Moritz, A., Krugluger, W., Huber, J. and Hopmeier, P. (2003) Plasminogen
- 17 activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu
- 18 polymorphism: impaired fibrinolysis and early pregnancy loss. *Clin Chem.*, **49**,

1 1081-6.

2 Eaton, D.L., Gallagher, E.P., Bammler, T.K. and Kunze, K.L. (1995) Role of
3 cytochrome P4501A2 in chemical carcinogenesis: implications for human
4 variability in expression and enzyme activity. *Pharmacogenetics*, **5**, 259-74.

5 Eskenazi, B., Mocarelli, P., Warner, M., Chee, W.Y., Gerthoux, P.M., Samuels, S.,
6 Needham, L.L. and Patterson, D.G. Jr. (2003) Maternal serum dioxin levels and
7 birth outcomes in women of Seveso, Italy. *Environ Health Perspect*, **111**, 947-53.

8 Fenster, L., Eskenazi, B., Windham, G.C. and Swan, S.H. (1991) Caffeine consumption
9 during pregnancy and spontaneous abortion. *Epidemiology*, **2**, 168-174.

10 Gardella, J.R. and Hill, J.A. III. (2000) Environmental toxins associated with recurrent
11 pregnancy loss. *Semin. Reprod. Med.* **18**, 407-424.

12 Hanna, I.H., Dawling, S., Roodi, N., Guengerich, F.P. and Parl, F.F. (2000)
13 Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of
14 polymorphisms with functional differences in estrogen hydroxylation activity.
15 *Cancer Res.*, **60**, 3440-4.

16 Karhukorpi, J., Laitinen, T., Kivela, H., Tiilikainen, A. and Hurme, M.. (2003) IL-1
17 receptor antagonist gene polymorphism in recurrent spontaneous abortion. J
18 *Reprod Immunol.*, **58**, 61-67.

- 1 Kawajiri, K., Watanabe, J., Eguchi, H., Nakachi, K., Kiyohara, C. and Hayashi, S.
2 (1995) Polymorphisms of human Ah receptor gene are not involved in lung cancer.
3 *Pharmacogenetics*, **5**, 151-8.
- 4 Kiyohara, C., Wakai, K., Mikami, H., Sido, K., Ando, M. and Ohno, Y. (2003) Risk
5 modification by CYP1A1 and GSTM1 polymorphisms in the association of
6 environmental tobacco smoke and lung cancer: a case-control study in Japanese
7 nonsmoking women. *Int J Cancer.*, **107**, 139-44.
- 8 Klebanoff, M.A., Levine, R.J., DerSimonian, R., Clemens, J.D. and Wilkins, D.G.
9 (1999) Maternal serum paraxanthine, a caffeine metabolite, and the risk of
10 spontaneous abortion. *N Engl J Med.*, **341**, 1639-44.
- 11 Landi, M.T., Bertazzi, P.A., Shields, P.G., Clark, G., Lucier, G.W., Garte, S.J., Cosma, G.
12 and Caporaso, N.E. (1994) Association between CYP1A1 genotype, mRNA
13 expression and enzymatic activity in humans. *Pharmacogenetics*, **4**, 242-246.
- 14 Larsen, M.C., Angus, W.G., Brake, P.B., Eltom, S.E., Sukow, K.A. and Jefcoate, C.R.
15 (1998) Characterization of CYP1B1 and CYP1A1 expression in human mammary
16 epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic
17 hydrocarbon metabolism. *Cancer Res.*, **58**, 2366-74.
- 18 Li, W., Harper, P.A., Tang, B.K. and Okey, A.B. (1998) Regulation of cytochrome

1 P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression
2 in the LS180 colon carcinoma cell line after treatment with
3 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. *Biochem Pharmacol.*,
4 **56**, 599-612.

5 Luch, A., Coffing, S.L., Tang, Y.M., Schneider, A., Soballa, V., Greim, H., Jefcoate,
6 C.R., Seidel, A., Greenlee, W.F., Baird, W.M. and Doehmer, J. (1998) Stable
7 expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and
8 metabolically catalyzed DNA adduct formation of dibenzo[a,l]pyrene. *Chem Res*
9 *Toxicol.*, **11**: 686-695.

10 McNulty, W. (1984) Fetocidal and teratogenic actions of TCDD. In: Lowrance, W.W.,
11 (ed.) *Public Health Risks of the Dioxins*. Proceedings of the Public Health Risks of
12 the Dioxins symposium, 19-20 October 1983, The Rockefeller University, New
13 York City. Los Altos, CA:Willam Kaufman, Inc., 245-253.

14 Murray, F.J., Smith, F.A., Nitschke, K.D., Humiston, C.G., Kociba, R.J. and Schwetz,
15 B.A. (1979) Three-generation reproduction study of rats given
16 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the diet. *Toxicol Appl Pharmacol.*,
17 **50**, 241-252.

18 Nau, H., Bass, R. and Neubert, D. (1986) Transfer, of

- 1 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) via placenta and milk, and postnatal
2 toxicity in the mouse. *Arch Toxicol.*, **59**, 36-40.
- 3 Nebert, D.W. and Gonzalez, F.J. (1987) P450 genes: structure, evolution and regulation.
4 *Annu. Rev. Biochem.*, **56**, 945–993.
- 5 Parazzini, F., Bocciolone, L., Fedele, L., Negri, E., La Vecchia, C and Acaia, B. (1991)
6 Risk factors for spontaneous abortion. *Int. J. Epidemiol.*, **20**, 157-161.
- 7 Pfeiffer, K.A., Fimmers, R., Engels, G., van der Ven, H. and van der Ven, K. (2001)
8 The HLA-G genotype is potentially associated with idiopathic recurrent
9 spontaneous abortion. *Mol Hum Reprod.*, **7**, 373-8.
- 10 Rey, E., Kahn, S.R., David, M. and Shrier, .I. (2003) Thrombophilic disorders and fetal
11 loss: a meta-analysis. *Lancet*, **361**, 901-8.
- 12 Sachse, C., Brockmoller, J., Bauer, S. and Roots, I. (1999) Functional significance of a
13 C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested
14 with caffeine. *Br J Clin Pharmacol.*, **47**, 445-9.
- 15 Safe, S.H. (1995) Modulation of gene expression and endocrine response pathways by
16 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. *Pharmac. Ther.*, **67**,
17 247–281.
- 18 Saijo, Y., Sata, F., Yamada, H., Kondo, T., Kato, E.H. and Kishi, R. (2004) Single

1 nucleotide polymorphisms in the promoter region of the interleukin-6 gene and the
2 risk of recurrent pregnancy loss in Japanese women. *Fertil Steril.*, **81**, 374-8.

3 Sasaki, M., Tanaka, Y., Kaneuchi, M., Sakuragi, N. and Dahiya, R. (2003) CYP1B1
4 gene polymorphisms have higher risk for endometrial cancer, and positive
5 correlations with estrogen receptor alpha and estrogen receptor beta expressions.
6 *Cancer Res.*, **63**, 3913-8.

7 Sata, F., Yamada, H., Kondo, T., Gong, Y., Tozaki, S., Kobashi, G., Kato, E.H.,
8 Fujimoto, S. and Kishi, R. (2003a) Glutathione S-transferase M1 and T1
9 polymorphisms and the risk of recurrent pregnancy loss. *Mol Hum Reprod*, **9**,
10 165-9.

11 Sata, F., Yamada, H., Yamada, A., Kato, E.H., Kataoka, S., Saijo, Y., Kondo, T., Tamaki,
12 J., Minakami, H. and Kishi, R. (2003b) A polymorphism in the CYP17 gene relates
13 to the risk of recurrent pregnancy loss. *Mol Hum Reprod.*, **9**, 725-8.

14 Signorello, L.B., Nordmark, A., Granath, F., Blot, W.J., McLaughlin, J.K., Anneren, G.,
15 Lundgren, S., Ekobom, A., Rane, A. and Cnattingius, S. (2001) Caffeine metabolism
16 and the risk of spontaneous abortion of normal karyotype fetuses. *Obstet Gynecol.*,
17 **98**, 1059-66.

18 Smart, J. and Daly, A.K. (2000) Variation in induced CYP1A1 levels: relationship to

1 CYP1A1, Ah receptor and GSTM1 polymorphisms. *Pharmacogenetics*, 10, 11-24.

2 Stirrat, G.M. (1990) Recurrent abortion. II. Clinical associations, causes, and
3 management. *Lancet*, **336**, 728-733.

4 Tang, Y.M., Wo, Y.Y., Stewart, J., Hawkins, A.L., Griffin, C.A., Sutter, T.R. and
5 Greenlee, W.F. (1996) Isolation and characterization of the human cytochrome
6 P450 CYP1B1 gene. *J Biol Chem.*, **271**, 28324-30.

7 Tempfer, C., Unfried, G., Zeillinger, R., Hefler, L., Nagele, F. and Huber, J.C. (2001)
8 Endothelial nitric oxide synthase gene polymorphism in women with idiopathic
9 recurrent miscarriage. *Hum Reprod.*, **16**, 644-7.

10 Tsuchiya, Y., Nakai, S., Nakamura, K., Hayashi, K., Nakanishi, J. and Yamamoto, M.
11 (2003) Effects of dietary habits and CYP1A1 polymorphisms on blood dioxin
12 concentrations in Japanese men. *Chemosphere*, **52**, 213-9.

13 Turesky, R.J., Constable, A., Richoz, J., Varga, N., Markovic, J., Martin, M.V. and
14 Guengerich, F.P. (1998) Activation of heterocyclic aromatic amines by rat and
15 human liver microsomes and by purified rat and human cytochrome P450 1A2.
16 *Chem Res Toxicol.*, **11**, 925-36.

17 Umbreit, T., Hesse, E. and Gallo, M. (1987) Reproductive toxicity in female mice of
18 dioxin-contaminated soils from a 2,4,5-trichlorophenoxyacetic acid manufacturing

1 site. *Arch Environ Contam Toxicol.*, **16**, 461-466.

2 Unfried, G., Tempfer, C., Schneeberger, C., Widmar, B., Nagele, F. and Huber, J.C.
3 (2001) Interleukin 1 receptor antagonist polymorphism in women with idiopathic
4 recurrent miscarriage. *Fertil Steril.*, **75**, 683-7.

5 Wang, X., Zuckerman, B., Pearson, C., Kaufman, G., Chen, C., Wang, G., Niu, T., Wise,
6 P.H., Bauchner, H. and Xu, X. (2002) Maternal cigarette smoking, metabolic gene
7 polymorphism, and infant birth weight. *JAMA.*, **287**, 241-242.

8 Wang, Z.C., Yunis, E.J., De los Santos, M.J., Xiao, L., Anderson, D.J., and Hill, J.A.
9 (2002) T helper 1-type immunity to trophoblast antigens in women with a history
10 of recurrent pregnancy loss is associated with polymorphism of the IL1B promoter
11 region. *Genes Immun.*, **3**, 38-42.

12 Watanabe, T., Imoto, I., Kosugi, Y., Fukuda, Y., Mimura, J., Fujii, Y., Isaka, K.,
13 Takayama, M., Sato, A. and Inazawa, J. (2001) Human arylhydrocarbon receptor
14 repressor (AHRR) gene: genomic structure and analysis of polymorphism in
15 endometriosis. *J Hum Genet.*, **46**, 342-6.

16 Williams, J.A. and Phillips, D.H. (2000) Mammary expression of xenobiotic
17 metabolizing enzymes and their potential role in breast cancer. *Cancer Res.*, **60**,
18 4667-77.

- 1 Wu, M.T., Ho, C.K., Huang, S.L., Yeh, Y.F., Liu, C.L., Mao, I.F. and Christiani, D.C.
2 (1999) Modulating influence of cytochrome P-450 MspI polymorphism on serum
3 liver function profiles in coke oven workers. *Occup. Environ. Med.*, **56**, 159-163.
- 4 Yamada, H., Kato, E.H., Kobashi, G., Ebina, Y., Shimada, S., Morikawa, M., Yamada,
5 T., Sakuragi, S. and Fujimoto, S. (2001) Recurrent pregnancy loss: etiology of
6 thrombophilia. *Semin. Thromb. Hemost.*, **27**, 121-129.
- 7 Yamada, H., Sata, F., Kato, E.H., Saijo, Y., Kataoka, S., Morikawa, M., Shimada, S.,
8 Yamada, T., Kishi, R. and Minakami, H. (2004) A polymorphism in the CYP17
9 gene and intrauterine fetal growth restriction. *Mol Hum Reprod.*, **10**, 49-53.
- 10 Yamada, H., Sata, F., Saijo, Y., Kishi, R. and Minakami, H. (2004) Genetic factors of
11 fetal growth restriction and miscarriage. *Semin Thromb Hemost* (in press)
- 12

1 **TABLE I. Characteristics of 113 cases with recurrent pregnancy loss (RPL) and**
 2 **203 controls in a Japanese population**

3

		Cases		Controls	
		Number	%	Number	%
Age					
	20-29	40	35.4	79	38.9
	30-39	63	55.8	112	55.2
	≥ 40	10	8.8	12	5.9
Pregnancy loss					
	2	47	41.6	—	—
	3	44	38.9	—	—
	≥ 4	22	29.5	—	—
	Primary RPL	99	87.6	—	—
	Secondary RPL	14	12.4	—	—
	< 9 weeks	62	54.9	—	—
	9-13 weeks	43	38.1	—	—
	≥ 14 weeks	8	7.1	—	—

4

5

1 **Table II.** Distribution of Ah receptor, CYP1A1, CYP1A2 and CYP1B1 genotypes
 2 among 113 cases with recurrent pregnancy loss and 203 controls

3

	Cases		Controls		OR* (95% CI)
	Number	%	Number	%	
4					
Ah receptor					
codon 554G/A					
Arg/Arg	36	31.9	49	24.1	(reference)
Arg/Lys	53	46.9	109	53.7	0.65 (0.38-1.12)
Lys/Lys	24	21.2	45	22.2	0.70 (0.36-1.36)
Arg/Lys+ Lys/Lys	77	68.1	154	75.9	0.67 (0.40-1.11)
CYP1A1 MspI					
m1m1	44	38.9	70	34.5	(reference)
m1m2	47	41.6	106	52.2	0.74 (0.44-1.24)
m2m2	22	19.5	27	13.3	1.39(0.70-2.77)
m1m2+m2m2	69	61.1	133	65.5	0.86 (0.53-1.40)
CYP1A2/D					
C/C	22	19.5	27	13.3	(reference)
C/A	47	41.6	106	52.2	0.53 (0.27-1.03)
A/A	44	39.8	70	34.5	0.72 (0.36-1.43)
A/A (vs C/C+C/A)	44	39.8	70	34.5	1.16 (0.71-1.88)
CYP1B1					
codon 432C/G					
Leu/Leu	85	75.2	158	77.8	(reference)
Leu/Val	25	22.1	41	20.2	1.15 (0.66-2.03)
Val/Val	3	2.7	4	2.0	1.42 (0.31-6.52)
Leu/Val+Val/Val	28	24.8	45	22.2	1.18 (0.68-2.02)

5 *Age-adjusted logistic regression analysis.

6

1 **TABLE III.** Distribution of Ah receptor, CYP1A1, CYP1A2 and CYP1B1 genotypes
 2 among 66 cases with three or more pregnancy losses and 203 controls

3
 4

	Cases		Controls		OR* (95% CI)
	Number	%	Number	%	
Ah receptor					
codon 554C/G					
Arg/Arg	22	33.3	49	24.1	(reference)
Arg/Lys	30	45.5	109	53.7	0.60 (0.31-1.15)
Lys/Lys	14	21.2	45	22.2	0.65 (0.30-1.44)
Arg/Lys+ Lys/Lys	44	66.7	154	75.9	0.62 (0.34-1.13)
CYP1A1 MspI					
m1m1	26	39.4	70	34.5	(reference)
m1m2	30	45.5	106	52.2	0.81 (0.44-1.50)
m2m2	10	15.2	27	13.3	1.11(0.47-2.65)
m1m2+m2m2	40	60.6	133	65.5	0.87 (0.49-1.55)
CYP1A2/D					
C/C	10	15.2	27	13.3	(reference)
C/A	30	45.5	106	52.2	0.73 (0.32-1.69)
A/A	26	39.4	70	34.5	0.90 (0.38-2.15)
A/A (vs C/C+C/A)	26	39.4	70	34.5	1.15 (0.64-2.06)
CYP1B1					
codon 432C/G					
Leu/Leu	49	74.2	158	77.8	(reference)
Leu/Val	15	22.7	41	20.2	1.22 (0.62-2.40)
Val/Val	2	3.0	4	2.0	1.66 (0.29-9.51)
Leu/Val+Val/Val	17	25.7	45	22.2	1.26 (0.66-2.41)

6 *Age-adjusted logistic regression analysis.

7